Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

66.50
-0.4600-0.69%
Post-market: 65.99-0.5100-0.77%19:30 EDT
Volume:2.06M
Turnover:137.93M
Market Cap:13.02B
PE:-18.63
High:67.59
Open:66.78
Low:66.15
Close:66.96
52wk High:93.42
52wk Low:52.75
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.69
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.18
PE(LYR):-17.57

Loading ...

BridgeBio Pharma is Maintained at Overweight by Barclays

Dow Jones
·
Yesterday

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)

TIPRANKS
·
Yesterday

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Yesterday

BridgeBio Pharma (BBIO) Receives a Buy from Barclays

TIPRANKS
·
Yesterday

Will Priority Review Change BridgeBio Pharma Stock Narrative

Simply Wall St.
·
Yesterday

BridgeBio to Present New Real-World Study Comparing Acoramidis vs Pfizer’s Tafamidis in ATTR-CM at HFSA 2026

Reuters
·
Yesterday

BridgeBio Rises on FDA Priority Review for Dwarfism Drug

Reuters
·
Oct 06

BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA

TIPRANKS
·
Oct 06

BridgeBio Pharma - to Submit Maa for Achondroplasia to Ema in Q4 2026

THOMSON REUTERS
·
Oct 06

BridgeBio Pharma - Anticipates U.S. Launch of Oral Infigratinib upon Approval

THOMSON REUTERS
·
Oct 06

BridgeBio Pharma - FDA Sets Pdufa Target Action Date of February 4, 2027 for Oral Infigratinib

THOMSON REUTERS
·
Oct 06

BridgeBio Announces FDA Acceptance and Priority Review of Nda for Oral Infigratinib for Children with Achondroplasia

THOMSON REUTERS
·
Oct 06

What Is Drawing Fresh Attention To BridgeBio Pharma (BBIO)?

Simply Wall St.
·
Oct 06

BridgeBio Says Interim Analysis of BBP-418 Showed Individuals Reaching Normal Levels on Limb-Girdle Muscular Dystrophy Markers

MT Newswires Live
·
Oct 05

BridgeBio Says Phase 3 Fortify Data Show BBP-418 Normalizes HS Troponin I in Lgmd2i/r9 Patients by Month 12

Reuters
·
Oct 05

Bbp-418 Demonstrates Potential to be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

THOMSON REUTERS
·
Oct 05

BridgeBio Pharma - Bbp-418 Met All Primary and Secondary Endpoints at 12-Month Interim Phase 3 Fortify Trial

THOMSON REUTERS
·
Oct 05

BridgeBio Pharma - 100% of Bbp-418-Treated Lgmd2i/R9 Patients Normalize Hs Troponin I at Month 12

THOMSON REUTERS
·
Oct 05

BridgeBio Pharma - Bbp-418 Under FDA Priority Review with Pdufa Date November 27, 2026

THOMSON REUTERS
·
Oct 05

Barclays Remains a Buy on BridgeBio Pharma (BBIO)

TIPRANKS
·
Sep 30